Statins benefit for kidney-transplant patients

Authors of a study published on THE LANCET’S website today (www.thelancet.com) highlight how statins (cholesterol-lowering drugs) could offer protection against cardiovascular disease for people who have undergone kidney transplantation.

Kidney-transplant patients are at an increased risk of premature cardiovascular disease; many transplant recipients have pre-existing cardiovascular disease at the time of transplantation and immunosuppressive therapy may aggravate existing risk factors or promote the development of new ones, notably high cholesterol concentration and high blood pressure. Statins have known benefits in reducing cardiovascular disease (including risk reduction among people with normal cholesterol concentrations), although their effect among kidney-transplant patients has not been proven.

In an international multicentre study, Hallvard Holdaas from Norway’s National hospital, Oslo, and colleagues investigated the effects of the statin fluvastatin in around 2100 people (from Belgium, Denmark, Finland, Germany, Norway, Sweden, Switzerland, the UK, and Canada) who had previously undergone kidney transplantation. All participants had baseline cholesterol concentrations between 4 and 9 millimols per litre; half were randomised to receive fluvastatin, the other half to placebo. Follow-up was done five to six years later. The primary endpoint was the occurrence of a major adverse cardiac event, defined as cardiac death, non-fatal myocardial infarction (MI), or coronary intervention procedure. Secondary endpoints included individual cardiac events, combined cardiac death or non-fatal MI, cerebrovascular events, non-cardiovascular death, and all-cause mortality.

People in the fluvastatin group had their cholesterol concentrations reduced by around a third compared with individuals given placebo. There were fewer cardiac deaths or non-fatal MI (70 compared with 104) in the fluvastatin group compared with placebo, although the overall difference in primary endpoints (including coronary intervention procedures) was not statistically significant compared with placebo.

Hallvard Holdaas comments: “As many as 50% of renal transplant recipients are now treated with statins, which reflects the widespread acceptance of data from other populations, particularly for the secondary prevention of cardiac disease and in diabetes. These other statin studies have shown that statins are effective in patients with mild renal failure who are at increased cardiovascular risk, some of whom may ultimately require renal transplantation. This study shows a similar beneficial effect for fluvastatin, a statin that has minimal interaction with immunosuppressive therapy, in patients at the opposite end of the spectrum of renal failure.”

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

New Milestone in Quantum Research

Google Quantum AI and quantum physicists at Freie Universität Berlin publish groundbreaking results on Hamiltonian operators. A research team including researchers at Freie Universität Berlin and Google Quantum AI has…

Breakthrough in photonic time crystals

… could change how we use and control light. The new discovery could dramatically enhance technologies like lasers, sensors and optical computing in the near future. An international research team…

Custom Print Heads for 3D Printing

Achieving Individual Functional Integration. Wire or Fiber Encapsulating Additive Manufacturing (WEAM/FEAM) could significantly simplify the industrial production of components that require the integration of complex yet compact wiring, sensors, actuators,…